生血合剂治疗再生障碍性贫血的临床研究

目的：观察生血合剂治疗再生障碍性贫血（简称再障）的临床疗效，探讨可能的疗效机理。方法：治疗组８４例，脾肾阳虚型用生血Ⅰ号合剂，脾肾阴虚型用生血Ⅱ号合剂治疗；对照组３０例用康力龙治疗，观察临床疗效和多项实验指标的变化。结果：治疗组基本治愈率，缓解率，总有效率分别为２１．４３％，２７．３８％，８６．９０％，对照组依次为３．３３％，２０．００％，５６．６７％，两组总胶前性差异，治疗组疗效明显优于对照组，

Clinical Study of Shengxue Mixture in Treating Aplastic Anemia

To observe the clinical effect of Shengxue mixture (SXM) in treating aplastic anemia, and studied its mechanism. Methods: Eighty-four patients of the treated group, those with Spleen-Kidney Yang deficiency Syndrome and Spleen-Kidney Yin deficiency Syndrone were treated with SXM-A and SXM-B respectively, and 30 patients of the control group were treated with Stanozolol. The clinical effect and several experimental parameters were also observed. Results: The basic cure rate, remission rate, total effective rate of the treated and control group were 21. 43%, 27.38%, 86.90% and 3.33%, 20.00%, 56.67% respectively, the difference between 2 groups was significant (P<0.05, P<0.01). The effect of the treated group was obviously better than that of the control group. While the patients' symptoms were alleviated, the peripheral blood cells increased, the ratio of T lymphocyte subsets tended to balance, the level of natural killer cells activity increased, interleukin 2 reduced, and the reproduction of the bone marrow were markedly improved in most of the patients treated by SXM. Conclusion: SXM is an effective and safe drug for aplastic anemia. Its mechanism might be regulating the immune function, which facilitated the recovery of the bone marrow hematopoiesis function.